The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Regulatory News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8 (OPD) (Midatech Pharma plc)

4 May 2020 07:00

RNS Number : 7369L
Midatech Pharma PLC
04 May 2020
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Midatech Pharma plc ("Midatech")

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Midatech Pharma plc

(d) Is the discloser the offeror or the offeree?

OFFEROR / OFFEREE

(e) Date position held:

The latest practicable date prior to the disclosure

1 May 2020

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

YES / NO / N/A

If YES, specify which:

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

n/a

n/a

(2) Cash-settled derivatives:

 

n/a

n/a

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

n/a

n/a

 

TOTAL:

n/a

n/a

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

n/a

Details, including nature of the rights concerned and relevant percentages:

n/a

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

Interest of Midatech Directors and connected advisers in Midatech shares:

Name

Number of Shares

% of issued share capital

Rolf Stahel

53,853

0.23

Stephen Stamp

50,000

0.21

Sijmen De Vries

26,242

0.11

Simon Turton

55,325

0.24

 

Interest of Midatech Directors in warrants over Midatech shares:

Name

Number of Warrants

Exercise price

Expiry date

Rolf Stahel

23,856

£10.00

26/02/2022

Sijmen De Vries

21,345

£10.00

26/02/2022

Simon Turton

41,855

£10.00

26/02/2022

 

Interest of Midatech Directors in options over Midatech shares:

Name

No. of options

Exercise price

Vesting date

Expiry date

Stephen Stamp

50,000

£1.05

20,000 if >$20m raised before 08/09/20, 7,500 on 09/09/20, 1,875 each of 12 quarters ending 09/12/23

02/10/2029

Sijmen de Vries

200

£83.80

Vested

20/04/2022

Sijmen de Vries

500

£1.50

Based on share price:

50% at £106.20; 25% at £274.40; 25% at £377.20

30/06/2024

 

 

 

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

YES/NO

Supplemental Form 8 (SBL)

YES/NO

 

 

Date of disclosure:

4 May 2020

Contact name:

Stephen Stamp

CEO/CFO

Telephone number:

+44 (0)1235 888300

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FEESSFFEDESSEFI
Date   Source Headline
10th Mar 20235:52 pmRNSFurther re: Notice of General Meeting
8th Mar 20237:00 amRNSPosting of Circular and Notice of General Meeting
17th Feb 20237:00 amRNSHolding(s) in Company
16th Feb 20237:00 amRNSHolding(s) in Company
15th Feb 20232:49 pmRNSHolding(s) in Company
15th Feb 20231:36 pmRNSHolding(s) in Company
15th Feb 20231:26 pmRNSHolding(s) in Company
15th Feb 20238:05 amRNSClosing of $6.0m Private Placement & Broker Change
9th Feb 20235:10 pmRNSPrivate Placement Raising US$6.0 million
3rd Feb 20239:57 amRNSReceipt of NASDAQ Notice
23rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
23rd Jan 20234:35 pmRNSPrice Monitoring Extension
23rd Jan 202312:00 pmRNSResult of General Meeting
16th Jan 202311:24 amRNSHolding(s) in Company
12th Jan 20237:00 amRNSPlanned Dose Escalation in MTX-110 Phase 1 Study
6th Jan 20237:00 amRNSPosting of Circular and Notice of General Meeting
19th Dec 202212:06 pmRNSHolding(s) in Company
19th Dec 202210:48 amRNSHolding(s) in Company
19th Dec 20227:00 amRNSClosing of Offering, Revised Terms, AIM & Webinar
14th Dec 20222:05 pmRNSSecond Price Monitoring Extn
14th Dec 20222:00 pmRNSPrice Monitoring Extension
13th Dec 20224:40 pmRNSSecond Price Monitoring Extn
13th Dec 20224:35 pmRNSPrice Monitoring Extension
13th Dec 20223:22 pmRNSProposed Acquisition of Bioasis Technologies Inc
14th Nov 20227:00 amRNSFirst Patient Enrolled in Phase 1 Study of MTX-110
18th Oct 20227:00 amRNSReceipt of NASDAQ Notification
20th Sep 202211:51 amRNSHolding(s) in Company
14th Sep 20221:57 pmRNSADR Ratio Change
14th Sep 20227:00 amRNSInterim results for the six months to 30 June 2022
21st Jun 20227:00 amRNSMTX110 Development for the Treatment of Glioma
20th Jun 20225:58 pmRNSDirectorate Change
20th Jun 20222:33 pmRNSResult of 2022 Annual General Meeting
10th Jun 20227:00 amRNSRetirement of Chairman and Proposed New Chairman
10th Jun 20227:00 amRNSMTX110 Study to be Presented at ISPNO 2022
1st Jun 202212:23 pmRNSFast Track Designation for MTX110 Development
24th May 202211:09 amRNSPosting of Annual Report & Notice of AGM
27th Apr 20221:00 pmRNSIssue of Equity for Employee Share Incentive Plan
26th Apr 20227:00 amRNSResults for the Year Ended 31 December 2021
14th Apr 202212:37 pmRNSReceipt of NASDAQ Notice
17th Mar 20227:00 amRNSExercise of Warrants and Issue of Equity
9th Mar 20227:00 amRNSR&D collaboration with Janssen on second molecule
8th Mar 20229:30 amRNSAppointment of Nominated and Financial Adviser
9th Feb 20221:53 pmRNSHolding(s) in Company
18th Jan 20224:18 pmRNSHolding(s) in Company
17th Jan 20227:00 amRNSExtension of Janssen collaboration re Q-Sphera
7th Jan 20225:37 pmRNSHolding(s) in Company
13th Dec 20219:43 amRNSIND Application for MTX110 Study in GBM Effective
3rd Dec 20217:00 amRNSMidatech presenting at MelloMonday
24th Nov 20217:00 amRNSMidatech presenting at the Shares/AJ Bell Webinar
17th Sep 20219:31 amRNSInterim results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.